Showing 4151-4160 of 9731 results for "".
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria
- Tarek El Hoss Named Sr. Vice President of Market Development and Sales at MedXhttps://practicaldermatology.com/news/tarek-el-hoss-named-sr-vice-president-of-market-development-and-sales-at-medx/2461287/Tarek El Hoss is MedX Health Corp.’s New Senior Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and g
- FDA Clears Use of Apyx Medical’s Renuvion Handpiece for Improvement in Appearance of Lax Skinhttps://practicaldermatology.com/news/fda-clears-use-of-apyx-medicals-renuvion-to-improve-appearance-of-lax-skin/2461273/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest
- Sun Safety Day at Wrigley a Success for Sun Heroeshttps://practicaldermatology.com/news/sun-safety-day-at-wrigley-a-success-for-sun-heroes/2461261/As an extension of the Sun Heroes initiative, CeraVe's Sun Safety Day at Wrigley Field in partnership with Amy Brodsky, MD brought sun protection education to attendees as the Chicago Cubs hosted the Atlanta Braves. Dr. Brodsky founded
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- Happify Health, Almirall Go Live with Digital Solution to Support Psoriasis Patientshttps://practicaldermatology.com/news/happify-health-almirall-go-live-with-digital-solution-to-support-psoriasis-patients/2461234/Happify Health and Almirall S.A.’s new digital platform Claro is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and m
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b